ABOUT US
Circadian Technologies Limited (ASX: CIR) is an emerging leader in the field of angiogenesis-based therapies for cancer and other serious human illnesses. Circadian’s strengths are the following:
Intellectual Property – Circadian owns the world’s largest and most comprehensive intellectual property estate covering the key angiogenesis targets VEGF-C, VEGF-D and VEGFR-3. These IP rights include over 50 patent families, 200 granted patents and 500 patents pending worldwide.
Pipeline – Circadian has an internal product pipeline comprising biologics drugs to three angiogenesis targets. Circadian’s most advanced program, VGX-100, an antibody-drug targeting VEGF-C, is expected to enter clinical trials in 2011.
Partners – Circadian has commercial partnerships with other leading biotechnology companies for development of products based upon the company’s technology. Ark Therapeutics is evaluating Trinam® in Phase 3 clinical trials. ImClone Systems is conducting preclinical studies of an anti-VEGFR-3 antibody for cancer treatment.
Management – Circadian’s management team and product development advisory group have an extensive track record of success establishing partnerships and bringing products to market.
Financial strength – Circadian has a strong financial position with over AU$59 million in cash and listed investments (end financial year 07/08). Circadian is an Australian biotechnology company focused on the development of biologics-based therapies for the treatment of cancer and other serious human illnesses. Under its subsidiary, Vegenics Limited, Circadian owns an extensive patent portfolio covering targets and drugs to modulate the process of angiogenesis – the development of blood vessels within the body. Inhibition of angiogenesis to essentially starve tumours of oxygen and nourishment has emerged in recent years as one of the most promising new methods for cancer treatment.